Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Beijing Normal Univ. CAIX compound [68Ga]Ga-14: sourced facts only. name: "[68Ga]Ga-14 bound recombinant human CAIX with high affinity (IC50 = 61 ± 9.5 nM)." [PMID:41544580]; target: "[68Ga]Ga-14 bound recombinant human CAIX with high affinity (IC50 = 61 ± 9.5 nM)." [PMID:41544580]; developer: "Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing, 100875, China." [PMID:41544580]; modality: "These findings identify [68Ga]Ga-14 as a highly promising CAIX-targeted PET tracer for sensitive detection of ccRCC, with potential for future theranostic applications." [PMID:41544580]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Beijing Normal Univ. CAIX compound [68Ga]Ga-14.